Graham Capital Management’s Emergent Biosolutions EBS Stock Holding History

Graham Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$181K	Buy	+21,592	New	+$181K	﹤0.01%	1068
2025 Q4	–	Sell	-51,072	Closed	-$450K	–	1314
2025 Q3	$450K	Buy	51,072 +11,812	+30%	+$91.9K	0.01%	655
2025 Q2	$250K	Buy	+39,260	New	+$225K	﹤0.01%	1054
2024 Q4	–	Sell	-36,692	Closed	-$306K	–	1293
2024 Q3	$306K	Sell	36,692 -7,183	-16%	-$65.3K	0.01%	773
2024 Q2	$299K	Buy	+43,875	New	+$189K	0.01%	733
2024 Q1	–	Sell	-36,637	Closed	-$87.9K	–	1127
2023 Q4	$87.9K	Buy	36,637 +23,986	+190%	+$56.4K	﹤0.01%	913
2023 Q3	$43K	Buy	+12,651	New	+$70.1K	﹤0.01%	969
2022 Q3	–	Sell	-6,626	Closed	-$205K	–	1117
2022 Q2	$205K	Sell	6,626 -4,493	-40%	-$153K	0.01%	920
2022 Q1	$456K	Buy	+11,119	New	+$490K	0.02%	584

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Graham Capital Management's EBS Position: Q2 2026 in Review

Graham Capital Management opened a new position in Emergent Biosolutions (EBS) in Q2 2026: 21,592 shares worth $181K. The stake represents ﹤0.01% of the portfolio and ranks #1068 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in EBS as recently as Q3 2025.

Graham Capital Management first reported a position in EBS in Q1 2022 and has held it in 9 quarters since. The position peaked at $456K in Q1 2022. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

Graham Capital Management held 21,592 shares of Emergent Biosolutions worth $181K as of Q2 2026.
Emergent Biosolutions was a new Graham Capital Management position in Q2 2026.
Emergent Biosolutions made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1068 holding.
Graham Capital Management first reported a position in Emergent Biosolutions in Q1 2022 and has held it in 9 quarters since.
Graham Capital Management's Emergent Biosolutions position peaked at $456K in Q1 2022.
195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.